187 related articles for article (PubMed ID: 37837883)
1. Podocyte injury of diabetic nephropathy: Novel mechanism discovery and therapeutic prospects.
Li X; Zhang Y; Xing X; Li M; Liu Y; Xu A; Zhang J
Biomed Pharmacother; 2023 Dec; 168():115670. PubMed ID: 37837883
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of podocyte injury and implications for diabetic nephropathy.
Barutta F; Bellini S; Gruden G
Clin Sci (Lond); 2022 Apr; 136(7):493-520. PubMed ID: 35415751
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of podocyte autophagy in the progression of diabetic nephropathy.
Yasuda-Yamahara M; Kume S; Tagawa A; Maegawa H; Uzu T
Autophagy; 2015; 11(12):2385-6. PubMed ID: 26565953
[TBL] [Abstract][Full Text] [Related]
4. Histone modification in podocyte injury of diabetic nephropathy.
Wang S; Zhang X; Wang Q; Wang R
J Mol Med (Berl); 2022 Oct; 100(10):1373-1386. PubMed ID: 36040515
[TBL] [Abstract][Full Text] [Related]
5. Research progress on exosomes in podocyte injury associated with diabetic kidney disease.
Li J; Zheng S; Ma C; Chen X; Li X; Li S; Wang P; Chen P; Wang Z; Li W; Liu Y
Front Endocrinol (Lausanne); 2023; 14():1129884. PubMed ID: 37020588
[TBL] [Abstract][Full Text] [Related]
6. miR-1187 induces podocyte injury and diabetic nephropathy through autophagy.
Chen B; He Q
Diab Vasc Dis Res; 2023; 20(3):14791641231172139. PubMed ID: 37208852
[TBL] [Abstract][Full Text] [Related]
7. Endothelial cell and podocyte autophagy synergistically protect from diabetes-induced glomerulosclerosis.
Lenoir O; Jasiek M; Hénique C; Guyonnet L; Hartleben B; Bork T; Chipont A; Flosseau K; Bensaada I; Schmitt A; Massé JM; Souyri M; Huber TB; Tharaux PL
Autophagy; 2015; 11(7):1130-45. PubMed ID: 26039325
[TBL] [Abstract][Full Text] [Related]
8. WT1 ameliorates podocyte injury via repression of EZH2/β-catenin pathway in diabetic nephropathy.
Wan J; Hou X; Zhou Z; Geng J; Tian J; Bai X; Nie J
Free Radic Biol Med; 2017 Jul; 108():280-299. PubMed ID: 28315733
[TBL] [Abstract][Full Text] [Related]
9. Podocyte Autophagy: A Potential Therapeutic Target to Prevent the Progression of Diabetic Nephropathy.
Liu N; Xu L; Shi Y; Zhuang S
J Diabetes Res; 2017; 2017():3560238. PubMed ID: 28512641
[TBL] [Abstract][Full Text] [Related]
10. Mangiferin prevents diabetic nephropathy progression and protects podocyte function via autophagy in diabetic rat glomeruli.
Wang X; Gao L; Lin H; Song J; Wang J; Yin Y; Zhao J; Xu X; Li Z; Li L
Eur J Pharmacol; 2018 Apr; 824():170-178. PubMed ID: 29444469
[TBL] [Abstract][Full Text] [Related]
11. Nicotine, smoking, podocytes, and diabetic nephropathy.
Jaimes EA; Zhou MS; Siddiqui M; Rezonzew G; Tian R; Seshan SV; Muwonge AN; Wong NJ; Azeloglu EU; Fornoni A; Merscher S; Raij L
Am J Physiol Renal Physiol; 2021 Mar; 320(3):F442-F453. PubMed ID: 33459165
[TBL] [Abstract][Full Text] [Related]
12. Molecular and cellular events mediating glomerular podocyte dysfunction and depletion in diabetes mellitus.
Anil Kumar P; Welsh GI; Saleem MA; Menon RK
Front Endocrinol (Lausanne); 2014; 5():151. PubMed ID: 25309512
[TBL] [Abstract][Full Text] [Related]
13. FOXO3a accumulation and activation accelerate oxidative stress-induced podocyte injury.
Chen X; Liu W; Xiao J; Zhang Y; Chen Y; Luo C; Huang Q; Peng F; Gong W; Li S; He X; Zhuang Y; Wu N; Liu Y; Wang Y; Long H
FASEB J; 2020 Oct; 34(10):13300-13316. PubMed ID: 32786113
[TBL] [Abstract][Full Text] [Related]
14. Ultrastructural changes in the glomerular filtration barrier and occurrence of proteinuria in Chinese patients with type 2 diabetic nephropathy.
Zhu WW; Chen HP; Ge YC; Xie HL; Zeng CH; Li LS; Liu ZH
Diabetes Res Clin Pract; 2009 Dec; 86(3):199-207. PubMed ID: 19815303
[TBL] [Abstract][Full Text] [Related]
15. ManNAc protects against podocyte pyroptosis via inhibiting mitochondrial damage and ROS/NLRP3 signaling pathway in diabetic kidney injury model.
Gao Y; Ma Y; Xie D; Jiang H
Int Immunopharmacol; 2022 Jun; 107():108711. PubMed ID: 35338958
[TBL] [Abstract][Full Text] [Related]
16. Angiopoietin-like protein 3 deficiency combined with valsartan administration protects better against podocyte damage in streptozotocin-induced diabetic nephropathy mice.
Ma Y; Xie D; Liu J; Han X; Xu H; Chen Y
Int Immunopharmacol; 2023 Feb; 115():109715. PubMed ID: 37724955
[TBL] [Abstract][Full Text] [Related]
17. ATF4-dependent heme-oxygenase-1 attenuates diabetic nephropathy by inducing autophagy and inhibiting apoptosis in podocyte.
Yuan S; Liang X; He W; Liang M; Jin J; He Q
Ren Fail; 2021 Dec; 43(1):968-979. PubMed ID: 34157937
[TBL] [Abstract][Full Text] [Related]
18. AMPK signalling: Implications for podocyte biology in diabetic nephropathy.
Szrejder M; Piwkowska A
Biol Cell; 2019 May; 111(5):109-120. PubMed ID: 30702162
[TBL] [Abstract][Full Text] [Related]
19. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice.
Inoki K; Mori H; Wang J; Suzuki T; Hong S; Yoshida S; Blattner SM; Ikenoue T; Rüegg MA; Hall MN; Kwiatkowski DJ; Rastaldi MP; Huber TB; Kretzler M; Holzman LB; Wiggins RC; Guan KL
J Clin Invest; 2011 Jun; 121(6):2181-96. PubMed ID: 21606597
[TBL] [Abstract][Full Text] [Related]
20. NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice.
Zhang L; Li R; Shi W; Liang X; Liu S; Ye Z; Yu C; Chen Y; Zhang B; Wang W; Lai Y; Ma J; Li Z; Tan X
Br J Pharmacol; 2013 Sep; 170(2):426-39. PubMed ID: 23826864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
